A Phase 3 interventional study of Ivacaftor and Tezacaftor/Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 68 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-01-08.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 21st largest by enrollment, is one of 8 that started in 2015, is one of 45 in phase 3, and was the 32nd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 8 started in 2015.
This study's enrollment of 156 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 35th largest by enrollment of the 116 interventional ones that give a count, is one of 12 that started in 2015, is one of 62 in phase 3, and was the 40th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ivacaftor 150 milligram (mg) tablet orally every 12 hours for 4 weeks.
Drug: Ivacaftor
VX-661 100 mg and ivacaftor 150 mg fixed-dose combination tablet orally once daily in the morning and ivacaftor 150 mg tablet orally once daily in the evening for 8 weeks.
Drug: Ivacaftor · Drug: Tezacaftor/Ivacaftor
Ivacaftor 150 mg tablet orally every 12 hours as monotherapy for 8 weeks.
Drug: Ivacaftor
Also known as: VX-770
Drug pages: Tezacaftor · Ivacaftor
Also known as: VX-661/VX-770
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Through Week 8
Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Through Week 8
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline Through Week 8
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Baseline, Through Week 8
Absolute Change From Baseline in Sweat Chloride Through Week 8
Sweat samples were collected using an approved collection device.
Time frame: Baseline, Through Week 8
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to Week 16
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)
Time frame: Predose on Week -2 for Run-in period; Pre-dose on Week 2 for Active comparator period
| Milestone | Ivacaftor (Run-in Period) | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) |
|---|---|---|---|
| Started | 156 | 0 | 0 |
| Completed | 153 | 0 | 0 |
| Not completed | 3 | 0 | 0 |
| Withdrew: Did not meet eligibility criteria | 1 | 0 | 0 |
| Withdrew: Participants refused further dosing | 2 | 0 | 0 |
| Milestone | Ivacaftor (Run-in Period) | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) |
|---|---|---|---|
| Started | 0 | 76 | 75 |
| Full analysis set | 0 | 76 | 74 |
| Completed | 0 | 75 | 69 |
| Not completed | 0 | 1 | 6 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Participants refused further dosing | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Other non-compliance | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 2 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| Percent predicted of FEV1 | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) |
|---|---|---|
| Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8 | 0.5 ± 0.4 | 0.2 ± 0.4 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| Percent change | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) |
|---|---|---|
| Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8 | 1.3 ± 0.6 | 0.5 ± 0.6 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) |
|---|---|---|
| Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline Through Week 8 | 0.7 ± 1.3 | -2.1 ± 1.3 |
Sweat samples were collected using an approved collection device.
| Millimoles per liter | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) |
|---|---|---|
| Absolute Change From Baseline in Sweat Chloride Through Week 8 | -7.9 ± 1.7 | -2.1 ± 1.8 |
| Participants | Ivacaftor (Run-in Period) | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) |
|---|---|---|---|
| Participants with AEs | 66 | 50 | 54 |
| Participants with SAEs | 2 | 4 | 7 |
| nanogram per milliliter (ng/mL) | Ivacaftor (Run-in Period) | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) |
|---|---|---|---|
| IVA | 812 ± 615 | 1000 ± 742 | 740 ± 464 |
| M1-IVA | 1590 ± 956 | 1830 ± 1010 | 1450 ± 828 |
| VX-661 | — | 2520 ± 1490 | — |
| M1-VX-661 | — | 4870 ± 1750 | — |
Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ivacaftor (Run-in Period) | 0/156 (0%) | 2/156 (1.3%) | 24/156 (15.4%) |
| VX-661 + Ivacaftor (Active Comparator Period) | 0/76 (0%) | 4/76 (5.3%) | 25/76 (32.9%) |
| Ivacaftor Monotherapy (Active Comparator Period) | 0/75 (0%) | 7/75 (9.3%) | 32/75 (42.7%) |
| Event | Ivacaftor (Run-in Period) | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) |
|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 1/156 | 2/76 | 5/75 |
| Idiopathic intracranial hypertensionNervous system disorders | 0/156 | 0/76 | 1/75 |
| Suicidal ideationPsychiatric disorders | 0/156 | 0/76 | 1/75 |
| Face oedemaGeneral disorders | 0/156 | 1/76 | 0/75 |
| Acute kidney injuryRenal and urinary disorders | 0/156 | 1/76 | 0/75 |
| UrticariaSkin and subcutaneous tissue disorders | 0/156 | 1/76 | 0/75 |
| Infective exacerbation of bronchiectasisInfections and infestations | 0/156 | 1/76 | 0/75 |
| InfluenzaInfections and infestations | 0/156 | 1/76 | 0/75 |
| Human rhinovirus test positiveInvestigations | 1/156 | 0/76 | 0/75 |
| PancreatitisGastrointestinal disorders | 1/156 | 0/76 | 0/75 |
| Event | Ivacaftor (Run-in Period) | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 12/156 | 12/76 | 12/75 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 8/156 | 4/76 | 7/75 |
| Viral upper respiratory tract infectionInfections and infestations | 1/156 | 4/76 | 6/75 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 2/156 | 6/76 | 4/75 |
| HeadacheNervous system disorders | 10/156 | 6/76 | 4/75 |
| FatigueGeneral disorders | 4/156 | 5/76 | 2/75 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 3/156 | 3/76 | 4/75 |
| NauseaGastrointestinal disorders | 3/156 | 0/76 | 4/75 |
| DizzinessNervous system disorders | 2/156 | 4/76 | 0/75 |
| DiarrhoeaGastrointestinal disorders | 2/156 | 4/76 | 1/75 |
Baseline analysis population included all participants who were included in Full Analysis Set for active comparator period (all randomized participants who have received at least 1 dose of blinded study drug during the active comparator treatment period.)
| Age, Continuous(years) | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) | Total |
|---|---|---|---|
| Mean | 33.0 ± 13.1 | 31.8 ± 11.1 | 32.4 ± 12.2 |
| Sex: Female, Male(Participants) | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) | Total |
|---|---|---|---|
| Female | 32 | 34 | 66 |
| Male | 44 | 40 | 84 |
| Ethnicity (NIH/OMB)(Participants) | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 76 | 72 | 148 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | VX-661 + Ivacaftor (Active Comparator Period) | Ivacaftor Monotherapy (Active Comparator Period) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 73 | 72 | 145 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Sep 2017, 27 months.
Results were first posted in Jan 2019, 1 year 4 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 27 months is close to that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ivacaftor · Tezacaftor
Vertex Pharmaceuticals Incorporated →